Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026Business Wire • 05/30/26
If Decades of History Tell Us Anything, This Biotech Near $50 Is Primed to Skyrocket24/7 Wall Street • 05/28/26
Exelixis, Inc. (EXEL) Presents at Bernstein 42nd Annual Strategic Decisions Conference TranscriptSeeking Alpha • 05/28/26
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in JuneBusiness Wire • 05/27/26
Caring Men Global Partners with Exelixis to Launch “Strong Caregivers, Stronger Survivors” Caregiver Training InitiativeBusiness Wire • 05/27/26
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch NearMarketBeat • 05/23/26
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor TypesBusiness Wire • 05/21/26
Exelixis, Inc. (EXEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum TranscriptSeeking Alpha • 05/20/26
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer StudyZacks Investment Research • 05/20/26
Exelixis, Inc. (EXEL) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/19/26
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal CancerBusiness Wire • 05/19/26
Exelixis, Inc. (EXEL) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/12/26
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in MayBusiness Wire • 05/07/26
Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 05/05/26
Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate UpdateBusiness Wire • 05/05/26
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026Business Wire • 04/21/26